Financial Data and Key Metrics Changes - The company reported a modest increase in its shareholder base, onboarding several new accounts interested in the HeartBeam offering [29] - Net current assets decreased by approximately 2 million in cash utilized during the quarter [35] Business Line Data and Key Metrics Changes - The company is pivoting towards companies that are closer to product revenue and value creation, indicating a shift in focus from deep tech ideas to more profitable ventures [19][48] - The company has three letters of intent (LOIs) with new companies, including a biotech firm with a pre-money valuation of 20 million, a profitable beverage company, and a healthcare software company [20][22][23] Market Data and Key Metrics Changes - The current venture market is characterized by a significant number of companies that have received funding but have not gone public, creating opportunities for the company to take these firms public [11][12] - The company noted a backlog of IPO opportunities due to changing market dynamics, with investors preferring companies that are capital light and closer to profitability [15][17] Company Strategy and Development Direction - The company aims to scale its operations by bringing three to four new investment opportunities to the public market each year, focusing on companies that can resonate in the changing marketplace [43][44] - The management emphasized the importance of valuation and the need to find extraordinary businesses at the right values to provide great return opportunities for investors [20][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the small IPO market, suggesting it will be robust and may reverse long-standing downtrends [17] - The management acknowledged the current challenging environment for small companies but remains confident in the company's ability to curate and take public viable businesses [24][49] Other Important Information - The company has restructured its executive compensation plan to align better with shareholder interests, converting a significant amount of stock compensation to options [31][32] - PatentVest is seen as a critical component for value creation, assisting in business development and strategy for the companies it works with [66][70] Q&A Session Summary Question: Can you talk about the company financing the 20 million for the potential cure for diabetes? - The company financing this is PaulX Bio [52] Question: How does management interpret the persistent discount of the MDBH stock price relative to the IPO price? - Management believes it is primarily a supply and demand issue, noting that market perceptions can change over time [54][56] Question: What is the future dividend policy? - The dividend policy will depend on the impact of share distribution on the companies involved and the company's cash flows [58][60] Question: How does the company make money when taking a venture public? - The company earns equity through pre-IPO financing and charges cash fees, often receiving a blend of cash and equity [62][63] Question: How much of MDB's value is due to its share of ownership of the companies taken public? - The company believes that if it had gone public at a better time, its valuation would be significantly higher [74][76] Question: Does the company consider acquisitions instead of IPOs? - Currently, the focus is on public ventures, but the company would consider acquisitions if they are accretive to its public venture strategy [79] Question: How many firms are doing what MDB Capital is doing currently? - Management believes there are very few firms left that can effectively take small companies public, highlighting the company's unique position [81][82]
MDB Capital (MDBH) - 2025 Q1 - Earnings Call Transcript